{"id":226224,"date":"2020-08-18T14:09:18","date_gmt":"2020-08-18T18:09:18","guid":{"rendered":"https:\/\/oncubanews.com\/en\/?p=226224"},"modified":"2020-08-18T14:09:18","modified_gmt":"2020-08-18T18:09:18","slug":"china-approves-patent-for-covid-19-vaccine-still-on-the-testing-phase","status":"publish","type":"post","link":"https:\/\/oncubanews.com\/en\/world\/china-approves-patent-for-covid-19-vaccine-still-on-the-testing-phase\/","title":{"rendered":"China approves patent for COVID-19 vaccine still on the testing phase"},"content":{"rendered":"

Help us keep OnCuba alive<\/strong><\/em><\/a><\/p>\n

The State Intellectual Property Office of China<\/a> (SIPO) approved the first patent for a COVID-19 vaccine candidate – still in the third phase of clinical trials – that could ‘be mass-produced in a short time\u201d, showed the local press this Monday.<\/p>\n

This vaccine, developed by the Military Scientific Institute and the Chinese biopharmaceutical company CanSino Biologics, began to be used in late June in the Chinese Army after a team led by researcher Chen Wei discovered a highly efficient neutralizing monoclonal antibody.<\/p>\n

The results of the second phase of clinical trials of the vaccine showed that it is safe and induces an immune response against the coronavirus<\/a>, according to research published at the end of July in The Lancet<\/em>.<\/p>\n

According to the SIPO patent, the vaccine has shown a “good immune response in mice and rodents, and it can induce the body to produce a strong cellular and humoral immune response in a short time”, reports the Cantonese newspaper Southern Metropolis<\/em>.<\/p>\n

The patent claims that this vaccine “can be mass-produced in a short time”, and that it is “quick and easy to prepare”. Its safety and effectiveness must be confirmed in phase three, which takes place abroad, the information adds.<\/p>\n

OMS dice tener \u201cbuenas noticias\u201d sobre vacuna contra COVID-19<\/a><\/p><\/blockquote>\n